A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Renal Cell Carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Mar 2024 This study has been Completed in Italy, According to European Clinical Trials Database record.
24 Oct 2023 Results of pooled meta analysis from NCT03203473, NCT03117309, NCT02917772 assessing to better inform the activity of N+I after N presented at the 48th European Society for Medical Oncology Congress
13 Oct 2023 Results assessing efficacy and safety of nivolumab and nivolumab plus ipilimumab combination(n=207),presented in the Lancet Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com